NEW YORK, Oct. 15, 2024 /PRNewswire/ — This Halloween, Monport Laser is giving laser engraving enthusiasts an exciting opportunity to win amazing prizes through the “Monport Halloween Hack” giveaway, a thrilling competition offering a chance to win incredible prizes and unleash your laser engraving creativity this spooky season.

Showcase Your Inner Spooktacular Artist and Win Big!

The “Monport Halloween Hack” invites participants to showcase their laser engraving talents with a Halloween twist. From October 15th, 2024, to October 30th, 2024, this spooky Halloween sale contest is open to all U.S. residents (excluding Hawaii, Alaska, and U.S. territories), aged 18 and above. Show your inner artist and create hauntingly beautiful laser-engraved projects.

Here’s a glimpse of the frightful good times that await:

Engrave Spooky Designs: Submit your laser-engraved Halloween project pictures and impress the judges with your Halloween Spooky creations.Spread the Haunt: Share your #MonportHalloweenHack posts on various platforms like laser forums, social media groups, and Reddit.Engage with Monport: Visit and subscribe to Monport Laser’s social media pages and YouTube channel to boost your entries.Refer a Friend: Share the spooky fun with your friends and earn extra entries!

Maximize Your Chances to Win!

How to Enter:

Participants can earn up to 33 entries by completing various actions on Monport Laser’s website. From engaging on social media to submitting laser-engraved Halloween project pictures, there are 12 unique ways to participate:

Submit a Monport Halloween Hack post on Laserengraverforum – 60 entriesSubmit a Monport Halloween Hack Blog Post – 50 entriesSubmit a Monport Halloween Hack Forum Post – 50 entriesSubmit your laser-engraved project pic – 30 entriesShare a laser-related post in a Facebook group – 50 entriesPost in a laser-related subreddit – 50 entriesVisit Monport Laser’s Facebook Page – 10 entriesVisit Monport Laser’s Instagram Page – 10 entriesSubmit a laser engraving project video with the Monport logo – 40 entriesVisit Monport Laser’s YouTube Page – 10 entriesSubscribe to the Monport Laser Newsletter – 10 entriesRefer friends for extra entries – 20 entries

Each confirmed entry will display a blue tick next to the corresponding action on the contest page. Head to Monport Laser’s Website for all the details and to start entering!

Boo-tiful Prizes Await!

The “Monport Halloween Hack” grand prize pool boasts an impressive selection of laser engravers and gift cards, perfect for elevating your laser engraving game. Here’s what you could win this Halloween sale:

Grand Prize (3 winners): 6W Diode Laser Engraver – valued at $599.99 each!First Place Prize (10 winners): 40W Pro Laser Engraver – valued at $499.99 each!Runner-Up Prize (20 winners): $100 Monport Laser Gift Card

The prize is non-transferable, non-exchangeable, and cannot be exchanged for cash.

Halloween Sale: Spooky Savings on Laser Engraving Equipment

In addition to the exciting giveaway, Monport Laser is offering a special Halloween sale featuring discounts on select laser engraving machines and accessories. Save up to $5,000 off on laser engraver machines and up to 30% Off on laser engraving accessories during this limited-time event.

Spin-to-Win for Free Laser Engraving Machines or Gift Cards

Monport Laser is introducing a thrilling spin-to-win game as part of the Halloween sale festivities. Visit the Monport Laser website during the Halloween sale period and spin the wheel to win a chance to receive a free laser engraving machine or gift card. It’s a fun and easy way to add even more excitement to your Halloween shopping experience.

Shop now and get ready for a spooktacular Halloween with Monport Laser!

Don’t Miss Out on the Spooky Fun!

Head over to https://monportlaser.com for complete details on how to enter, terms & conditions, and to unleash your Halloween laser engraving creativity.

Join the #MonportHalloweenHack and let the spooky engraving begin!

Winner Announcement

Winners will be chosen randomly from eligible participants and notified by email on November 5, 2024. The winners’ names will also be published on Monport’s website and shared via Monport’s official Instagram page @monportlaserofficialus. If a winner doesn’t respond within 7 days, their prize will be forfeited, and a new winner will be selected.

Terms & Conditions

By entering the Monport Halloween Hack Grand Gifts Giveaway, participants agree to Monport’s terms and conditions, including consenting to receive Monport marketing materials. All personal information collected will be used solely for the purposes of administering the competition and will not be shared with third parties.

This Halloween sale giveaway is not affiliated with or sponsored by Instagram, Facebook, or YouTube.

About Monport Laser

Monport Laser is a leading provider of high-quality laser engravers and cutters, offering products that cater to hobbyists, small businesses, and professionals alike. Known for their precision, durability, and innovation, Monport’s laser machines empower creators to bring their visions to life.

For more information about the Monport Halloween Hack Grand Gifts Giveaway or Monport Laser products, visit https://monportlaser.com and join the creative community today!

Learn more at: https://monportlaser.com/

For updates, follow Monport on social media:

Instagram: https://www.instagram.com/monportlaserofficial/

Youtube: https://www.youtube.com/@monportlaser/

View original content:https://www.prnewswire.com/news-releases/showcase-your-spooky-skills-with-monport-spooktacular-laser-engraving-giveaway-302276372.html

SOURCE Monport Laser

First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium

Self-collection option available at no extra charge at any of Quest’s 2,000 patient service centers with a physician’s order or through Quest’s consumer-initiated test platform at questhealth.com

SECAUCUS, N.J., Oct. 15, 2024 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the availability of a new service aimed at increasing convenience and speed of testing and treatment of several common genital tract infections (GTIs). Quest is the first laboratory provider to offer patients experiencing vaginitis and symptoms of similar common GTIs the option to self-collect a swab specimen on a national scale, supporting patient care, the drive for greater patient choice, and empowerment in healthcare.

“Quest is constantly looking for ways to meet the needs of the communities we serve to empower choice and convenience as well as better health outcomes. Giving patients the option to self-collect in our patient service centers will increase access to important sexual health testing for many,” said Kathleen Valentine, Vice President and General Manager of Women’s and Reproductive Health Services at Quest Diagnostics.

The new offering utilizes the FDA-cleared Aptima® Multi-test swab for patient-collected vaginal specimens. The FDA cleared the swab for patient self-collection in clinical settings, such as those of Quest’s patient service centers or in traditional clinical settings like a doctor’s office. It is not FDA cleared for at-home collection, and self-collection is not intended to replace a pelvic examination provided by a clinician. Patients should inform their healthcare provider if they suspect that they are pregnant or if they have recently had symptoms of pelvic inflammatory disease (such as pelvic pain, pain with sexual intercourse, unusual vaginal discharge or bad odor).

When testing for genital tract infections in conventional practice, a healthcare provider collects a specimen from a patient in their office or clinic and forwards it to a laboratory for testing. With the new Quest self-collection service, patients with symptoms may, with an electronically placed physician’s order, vaginally self-collect in a private room at a Quest Diagnostics patient service center using a simple step-by-step guide. Collection directions will be provided for self-collections, however some patients may experience difficulty with self-collection and may require a visit to their healthcare provider to assist with the collection. The Quest Diagnostics patient service center will send the specimen to the testing laboratory. Test results are provided to the provider and patient electronically. The provider may review the results and provide treatment during a separate patient visit and provide further evaluation as needed. The self-collect option is available at no extra charge for the patient or health plan.

“Unidentified and untreated GTIs can lead to serious, long-term health issues, such as pelvic inflammatory disease, infertility, chronic pelvic pain or problems in pregnancy,” said board-certified obstetrician and gynecologist Damian P. Alagia, MD, Senior Medical Director, Women’s Health, Quest Diagnostics. “Specimen self-collection has been shown to appeal to many female patients as an alternative to a provider-performed collection but with comparable accuracy. I am confident that our specimen self-collection option will help women feel more comfortable seeking out the testing they need.”

The new collection method may be used for laboratory testing of six common infections and causes of vaginitis, which affects one in three women in their lifetime1, including bacterial vaginosis (BV), vulvovaginal candidiasis (yeast infection) and trichomoniasis. It may also be used to test for similar common GTIs including chlamydia, gonorrhea, and Mycoplasma genitalium. Vaginitis is a highly common condition that can cause irritation and discomfort. It may be due to any number of factors that include certain sexually transmitted infections and similar genital tract conditions such as bacterial vaginosis/vaginitis and candidiasis.

The new offering provides more choice to patients interested in a discreet method of collection, improves access to testing and treatment, and reduces pressure on physicians and other healthcare professionals to accommodate patients requiring urgent evaluation. This capability comes at a time when emerging solutions allow for specimen collection in new and various settings, enabling more accessible care. In a recent survey, 51% of respondents cited convenience and ease of access as the most important factors in healthcare decision making.2

For more information on the company’s GTI clinical offerings for physician order, visit www.QuestWomensHealth.com.

Choosing the specimen self-collection option via questhealth.com

In addition to the physician channel, patients may also utilize the specimen self-collection option when ordering laboratory testing for one or more GTIs via Quest’s consumer-initiated testing platform, questhealth.com. Individuals who purchase testing through questhealth.com are able to discuss test results with a licensed physician from PWNHealth, an independent, third-party physician network. In addition, the physician may be able to provide treatment and prescribe medication for certain conditions based on test results.

With the availability of the new collection method at Quest’s 2,000 patient service centers, several existing questhealth.com offerings have been updated to include the option to self-collect a specimen, including the Chlamydia & Gonorrhea Test, Trichomonas Test, Mycoplasma genitalium Test, the Basic and Expanded STD Screening Panels, and the recently introduced Bacterial Vaginosis and Vaginitis Test Panel Tests.

About Quest Diagnostics

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world’s largest databases of de-identifiable clinical lab results, Quest’s diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

1 Vodstrcil LA, Plummer EL, Doyle M, Fairley CK, McGuiness C, Bateson D, Hocking JS, Law MG, Petoumenos K, Donovan B, Chow EPF, Bradshaw CS; StepUp RCT Team. Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence. BMC Infect Dis. 2020 Nov 11;20(1):834. doi: 10.1186/s12879-020-05563-w. PMID: 33176727; PMCID: PMC7661182.
2 2019 Healthcare Consumer Trends Report (nrchealth.com)

View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-introduces-specimen-self-collection-for-common-genital-tract-infection-testing-at-nationwide-network-of-patient-service-centers-302276375.html

SOURCE Quest Diagnostics

Lumachain’s SaaS platform uses Computer Vision-based Artificial Intelligence to enhance safety, yield, efficiency, quality, traceability, and trust in food productionBrassica is a Mediterranean inspired sandwich and salad concept committed to wholesome ingredients and sustainable practices

NEWPORT BEACH, Calif., Oct. 15, 2024 /PRNewswire/ — Chipotle Mexican Grill (NYSE: CMG) today announced it is making a minority investment in Lumachain, an AI supply chain platform, and Brassica, a fast-casual restaurant concept, through its $100 million Cultivate Next venture fund. Introduced in 2022, Cultivate Next makes early-stage investments into strategically aligned companies that further Chipotle’s mission to Cultivate a Better World and help accelerate the company’s longer term growth plans to operate 7,000 restaurants in North America.

Lumachain
Headquartered in Sydney, Australia, Lumachain’s mission is to improve how food is produced, for good. The minority female-founded company has developed a traceability solution that, in real-time, tracks the origin, location, and condition of individual items in a supply chain, from farm to table, enabling reduced waste and increased efficiency. Lumachain’s traceability platform is complemented by its Computer Vision AI platform that monitors operations inside food production plants, to improve quality, efficiency and safety.

“The visibility in real time and quality data analytics that Lumachain’s software provides could optimize the management and quality of perishable goods for the food service industry,” said Curt Garner, Chief Customer and Technology Officer, Chipotle.

Brassica
The Columbus, Ohio based fast-casual restaurant serves wholesome, Eastern Mediterranean-inspired cuisine for guests to personalize their own salads and sandwiches. Founded in 2015, Brassica is committed to using high quality, locally-sourced ingredients at its six restaurant locations. The concept provides healthy dining options without compromising flavor. It includes a front-line ordering experience and a welcoming atmosphere defined by natural materials and standout architectural details. Signature items include house-made falafel, baked-to-order organic pita, antibiotic-free meats, roasted vegetables, Brassica seasoned fries, vegan tahini chocolate chip cookies, and fresh-squeezed minty pink lemonade.

“Investing in emerging culinary concepts that align with Chipotle’s commitment to using real, fresh ingredients and making craveable food daily is consistent with our mission to Cultivate a Better World,” said Nate Lawton, Chief Business Development Officer, Chipotle. “Funding from Cultivate Next’s minority investment will help Brassica scale to open new locations and expand to new markets.”

Chipotle’s Cultivate Next venture fund portfolio includes: Brassica, GreenField Robotics, Hyphen, Local Line, Lumachain, Meati Foods, Nitricity, Vebu, and Zero Acre Farms. Companies interested in collaborating with Chipotle through the Cultivate Next venture fund can apply by emailing CultivateNext@Chipotle.com.

ABOUT CHIPOTLE
Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. There are over 3,500 restaurants as of June 30, 2024, in the United States, Canada, the United Kingdom, France, Germany, and Kuwait and it is the only restaurant company of its size that owns and operates all its restaurants in North America and Europe. Chipotle is ranked on the Fortune 500 and is recognized on Fortune’s Most Admired Companies 2024 list and Time Magazine’s Most Influential Companies. With over 120,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. For more information or to place an order online, visit Chipotle.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/chipotles-cultivate-next-fund-invests-in-ai-supply-chain-solution-and-emerging-fast-casual-concept-302276119.html

SOURCE Chipotle Mexican Grill